CLs were detected in 328 patients with MS (59.9%), 24 with CIS (49.0%), 1 with AQP4-positive NMOSD (5.3%), 3 with seronegative-NMOSD (13.6%), 4 with MOGAD (23.5%), 1 with migraine (1.1%), 7 with inflammatory vasculopathies (24.1%), 9 with cerebrovascular disease (14.3%), 0 with Fabry disease, and 4 healthy control individuals (2.7%). The gene discussed is AQP4; the disease is in situ carcinoma.